Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA Panel To Take Second Look After J&J Plugged Holes In Xarelto ATLAS Data

This article was originally published in The Pink Sheet Daily

Executive Summary

Broader issue of missing data in clinical trials could see further discussion as FDA’s Cardiovascular and Renal Advisory Committee will relook at Xarelto’s acute coronary syndrome indication Jan. 16, now that J&J has tried to address the missing data that befuddled the committee on the first go-round.

Advertisement

Related Content

J&J To Persevere In ACS After Another “Complete Response” For Xarelto
Xarelto Label Expansion Plans Slowed By FDA “Complete Response” On ACS Claim
FDA Panel Looks Beyond Xarelto’s Missing Data Problems To Broader Reforms
ATLAS Data Not Strong Enough To Support Xarelto’s Use In ACS, FDA Panel Says
Xarelto Acute Coronary Syndromes Claim Faces Data Quality Hurdle
FDA Advice On Missing Data May Be To Avoid Missing It In The First Place

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS075172

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel